首页 > 最新文献

Journal of Biomolecular Structure & Dynamics最新文献

英文 中文
Structural and functional implications of ABCC1 variants on clinical statin response. ABCC1变异对临床他汀类药物反应的结构和功能影响。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2025-03-08 DOI: 10.1080/07391102.2025.2475225
Naomí Crispim Tropéia, Paula Paccielli Freire, Eduardo Willian de Alencar Pereira, Marcelo Ferraz Sampaio, Jéssica Bassani Borges, Gisele Medeiros Bastos, Helena Strelow Thurow, Lara Reinel Castro, Marcelo Arruda Nakazone, Tayanne Silva Carmo, Mario Hiroyuki Hirata, Glaucio Monteiro Ferreira

ATP-binding cassette (ABC) proteins are membrane transporters responsible for metabolites and active substances removal from cells. Their genes' variations have been associated with protein function and expression defects. Familial Hypercholesterolemia (FH) patients hosting those alterations might compromise the efficacy of high-dose statin treatment, a primary therapeutic strategy. ABCC1 is a member of the ABC-transporter superfamily, potentially relevant to pharmacological therapy responses and toxicity risks in hypercholesterolemic patients. Here, we evaluated specific non-synonymous (SNV) missense variants in the ABCC1 gene from a FH patient cohort, assessing potential impacts on protein structure, molecular dynamics and interactions with rosuvastatin, atorvastatin, pravastatin, pitavastatin, and lovastatin. Molecular docking, complemented by motion, visual and binding affinity analysis using the PLANNET model, suggested that these mutations had minimal impact on drug interactions. These findings prompted further analysis of two other efflux pumps, ABCG2 and P-gp, and their statin interactions. Interestingly, diminished binding affinities hinted at a compensatory mechanism wherein other transporters might mitigate potential ABCC1 mutation effects, ensuring effective drug efflux. Clinical profiles from the patient cohort did not show a correlation between these variants and clinical outcomes, potentially pointing to the role of alternate drug transporters in statin interaction.

atp结合盒(ABC)蛋白是负责代谢产物和活性物质从细胞中去除的膜转运蛋白。他们的基因变异与蛋白质功能和表达缺陷有关。家族性高胆固醇血症(FH)患者存在这些改变可能会影响大剂量他汀类药物治疗的疗效,而他汀类药物是主要的治疗策略。ABCC1是abc转运蛋白超家族的一员,可能与高胆固醇血症患者的药物治疗反应和毒性风险有关。在这里,我们评估了来自FH患者队列的ABCC1基因的特定非同义(SNV)错义变异,评估了对蛋白质结构、分子动力学以及与瑞舒伐他汀、阿托伐他汀、普伐他汀、匹伐他汀和洛伐他汀的相互作用的潜在影响。分子对接,辅以运动、视觉和结合亲和力分析,使用PLANNET模型,表明这些突变对药物相互作用的影响很小。这些发现促使进一步分析另外两种外排泵,ABCG2和P-gp,以及它们与他汀类药物的相互作用。有趣的是,结合亲和力的降低暗示了一种代偿机制,其中其他转运蛋白可能减轻潜在的ABCC1突变效应,确保有效的药物外排。来自患者队列的临床资料未显示这些变异与临床结果之间的相关性,这可能表明替代药物转运体在他汀类药物相互作用中的作用。
{"title":"Structural and functional implications of ABCC1 variants on clinical statin response.","authors":"Naomí Crispim Tropéia, Paula Paccielli Freire, Eduardo Willian de Alencar Pereira, Marcelo Ferraz Sampaio, Jéssica Bassani Borges, Gisele Medeiros Bastos, Helena Strelow Thurow, Lara Reinel Castro, Marcelo Arruda Nakazone, Tayanne Silva Carmo, Mario Hiroyuki Hirata, Glaucio Monteiro Ferreira","doi":"10.1080/07391102.2025.2475225","DOIUrl":"10.1080/07391102.2025.2475225","url":null,"abstract":"<p><p>ATP-binding cassette (ABC) proteins are membrane transporters responsible for metabolites and active substances removal from cells. Their genes' variations have been associated with protein function and expression defects. Familial Hypercholesterolemia (FH) patients hosting those alterations might compromise the efficacy of high-dose statin treatment, a primary therapeutic strategy. <i>ABCC1</i> is a member of the ABC-transporter superfamily, potentially relevant to pharmacological therapy responses and toxicity risks in hypercholesterolemic patients. Here, we evaluated specific non-synonymous (SNV) missense variants in the <i>ABCC1</i> gene from a FH patient cohort, assessing potential impacts on protein structure, molecular dynamics and interactions with rosuvastatin, atorvastatin, pravastatin, pitavastatin, and lovastatin. Molecular docking, complemented by motion, visual and binding affinity analysis using the PLANNET model, suggested that these mutations had minimal impact on drug interactions. These findings prompted further analysis of two other efflux pumps, <i>ABCG2</i> and <i>P-gp</i>, and their statin interactions. Interestingly, diminished binding affinities hinted at a compensatory mechanism wherein other transporters might mitigate potential <i>ABCC1</i> mutation effects, ensuring effective drug efflux. Clinical profiles from the patient cohort did not show a correlation between these variants and clinical outcomes, potentially pointing to the role of alternate drug transporters in statin interaction.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"1089-1102"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
β-1,3-glucan from Euglena gracilis: a promising epidrug targeting epigenetic regulators PRMTs and SIRTs for therapeutic applications in ovarian cancer. 来自褐藻的β-1,3-葡聚糖:一种有望用于卵巢癌治疗的、靶向表观遗传调控因子 PRMTs 和 SIRTs 的表皮药物。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-11-13 DOI: 10.1080/07391102.2024.2425832
Varsha Virendra Palol, Kamran Waidha, Balasubramanian Moovarkumudalvan, Navya Valavath Baburajan, Suresh Kumar Saravanan, Divya Lakshmanan, Veni Subramanyam, Raj Kumar Chinnadurai

Natural products serve as a valuable resource in drug discovery and the identification of bioactive molecules in the field of epimedicine, which targets epigenetic regulator enzymes through epidrugs. In this study, β-1,3-glucan (BG), a natural storage polysaccharide in Euglena gracilis, a well-known immunostimulatory agent, is propounded as a promising epidrug. To elucidate the therapeutic efficacy of BG against ovarian cancer, the molecular interactions between BG and epigenetic regulators, Protein Arginine Methyltransferases (PRMTs) and Sirtuins (SIRTs) were investigated using computational methods followed by in vitro gene expression studies in SKOV-3 ovarian cancer cell line. The binding energies of PRMT5 and SIRT5 against BG were observed as -65.5 and -68.2 kcal/mol, respectively. The in vitro cytotoxic effects of BG against human ovarian cancer cell line, SKOV-3 showed an IC50 of 150 µg/mL at 48 h. Significant epigenetic modifications were observed to be influenced by BG which increased the gene expression of PRMT5, SIRT5 and Nrf2 to 0.3, 0.5, and 0.7 fold-change respectively, while the Nrf1/2 plasmid showed reduced reporter activity by 29%. Collectively, both in silico and in vitro studies provided valuable insights into the epigenetic regulation of PRMT5 and SIRT5 by BG via Nrf1/2. Nonetheless, further preclinical and clinical investigations are essential to validate the therapeutic properties of BG as an epidrug against ovarian cancer.

天然产物是表观医学领域药物发现和生物活性分子鉴定的宝贵资源,表观医学通过表观药物靶向表观遗传调节酶。在这项研究中,β-1,3-葡聚糖(BG)被认为是一种有前景的表观药物,β-1,3-葡聚糖是Euglena gracilis的一种天然贮存多糖,也是一种著名的免疫刺激剂。为了阐明 BG 对卵巢癌的疗效,研究人员使用计算方法研究了 BG 与表观遗传调控因子、精氨酸甲基转移酶(PRMTs)和 Sirtuins(SIRTs)之间的分子相互作用,随后在 SKOV-3 卵巢癌细胞系中进行了体外基因表达研究。结果表明,PRMT5 和 SIRT5 与 BG 的结合能分别为 -65.5 和 -68.2 kcal/mol。BG对人类卵巢癌细胞株SKOV-3的体外细胞毒性作用显示,48小时后的IC50为150微克/毫升。BG对表观遗传修饰有显著影响,使PRMT5、SIRT5和Nrf2的基因表达分别增加了0.3、0.5和0.7倍,而Nrf1/2质粒的报告活性降低了29%。总之,硅学和体外研究为 BG 通过 Nrf1/2 对 PRMT5 和 SIRT5 进行表观遗传调控提供了有价值的见解。然而,进一步的临床前和临床研究对于验证 BG 作为一种表观药物对卵巢癌的治疗特性至关重要。
{"title":"β-1,3-glucan from <i>Euglena gracilis</i>: a promising epidrug targeting epigenetic regulators PRMTs and SIRTs for therapeutic applications in ovarian cancer.","authors":"Varsha Virendra Palol, Kamran Waidha, Balasubramanian Moovarkumudalvan, Navya Valavath Baburajan, Suresh Kumar Saravanan, Divya Lakshmanan, Veni Subramanyam, Raj Kumar Chinnadurai","doi":"10.1080/07391102.2024.2425832","DOIUrl":"10.1080/07391102.2024.2425832","url":null,"abstract":"<p><p>Natural products serve as a valuable resource in drug discovery and the identification of bioactive molecules in the field of epimedicine, which targets epigenetic regulator enzymes through epidrugs. In this study, β-1,3-glucan (BG), a natural storage polysaccharide in <i>Euglena gracilis,</i> a well-known immunostimulatory agent, is propounded as a promising epidrug. To elucidate the therapeutic efficacy of BG against ovarian cancer, the molecular interactions between BG and epigenetic regulators, Protein Arginine Methyltransferases (PRMTs) and Sirtuins (SIRTs) were investigated using computational methods followed by <i>in vitro</i> gene expression studies in SKOV-3 ovarian cancer cell line. The binding energies of PRMT5 and SIRT5 against BG were observed as -65.5 and -68.2 kcal/mol, respectively. The <i>in vitro</i> cytotoxic effects of BG against human ovarian cancer cell line, SKOV-3 showed an IC<sub>50</sub> of 150 µg/mL at 48 h. Significant epigenetic modifications were observed to be influenced by BG which increased the gene expression of PRMT5, SIRT5 and Nrf2 to 0.3, 0.5, and 0.7 fold-change respectively, while the Nrf1/2 plasmid showed reduced reporter activity by 29%. Collectively, both <i>in silico</i> and <i>in vitro</i> studies provided valuable insights into the epigenetic regulation of PRMT5 and SIRT5 by BG <i>via</i> Nrf1/2. Nonetheless, further preclinical and clinical investigations are essential to validate the therapeutic properties of BG as an epidrug against ovarian cancer.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"667-682"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MCNN-AAPT: accurate classification and functional prediction of amino acid and peptide transporters in secondary active transporters using protein language models and multi-window deep learning. MCNN-AAPT:利用蛋白质语言模型和多窗口深度学习对二级活性转运体中的氨基酸和肽转运体进行精确分类和功能预测。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-11-22 DOI: 10.1080/07391102.2024.2431664
Muhammad Shahid Malik, Van The Le, Syed Muazzam Ali Shah, Yu-Yen Ou

Secondary active transporters play a crucial role in cellular physiology by facilitating the movement of molecules across cell membranes. Identifying the functional classes of these transporters, particularly amino acid and peptide transporters, is essential for understanding their involvement in various physiological processes and disease pathways, including cancer. This study aims to develop a robust computational framework that integrates pre-trained protein language models and deep learning techniques to classify amino acid and peptide transporters within the secondary active transporter (SAT) family and predict their functional association with solute carrier (SLC) proteins. The study leverages a comprehensive dataset of 448 secondary active transporters, including 36 solute carrier proteins, obtained from UniProt and the Transporter Classification Database (TCDB). Three state-of-the-art protein language models, ProtTrans, ESM-1b, and ESM-2, are evaluated within a deep learning neural network architecture that employs a multi-window scanning technique to capture local and global sequence patterns. The ProtTrans-based feature set demonstrates exceptional performance, achieving a classification accuracy of 98.21% with 87.32% sensitivity and 99.76% specificity for distinguishing amino acid and peptide transporters from other SATs. Furthermore, the model maintains strong predictive ability for SLC proteins, with an overall accuracy of 88.89% and a Matthews Correlation Coefficient (MCC) of 0.7750. This study showcases the power of integrating pre-trained protein language models and deep learning techniques for the functional classification of secondary active transporters and the prediction of associated solute carrier proteins. The findings have significant implications for drug development, disease research, and the broader understanding of cellular transport mechanisms.

二级活性转运体通过促进分子在细胞膜上的移动,在细胞生理学中发挥着至关重要的作用。识别这些转运体的功能类别,特别是氨基酸和肽转运体,对于了解它们参与各种生理过程和疾病(包括癌症)的途径至关重要。本研究旨在开发一个强大的计算框架,将预先训练好的蛋白质语言模型与深度学习技术相结合,对二级活性转运体(SAT)家族中的氨基酸和肽转运体进行分类,并预测它们与溶质载体(SLC)蛋白的功能关联。这项研究利用了从UniProt和转运体分类数据库(TCDB)获得的448个二级活性转运体的综合数据集,其中包括36个溶质载体蛋白。在采用多窗口扫描技术捕捉局部和全局序列模式的深度学习神经网络架构中,对 ProtTrans、ESM-1b 和 ESM-2 这三种最先进的蛋白质语言模型进行了评估。基于 ProtTrans 的特征集表现出卓越的性能,在区分氨基酸和肽转运体与其他 SAT 时,分类准确率达到 98.21%,灵敏度为 87.32%,特异度为 99.76%。此外,该模型对 SLC 蛋白保持了很强的预测能力,总体准确率为 88.89%,马修斯相关系数 (Matthews Correlation Coefficient, MCC) 为 0.7750。这项研究展示了将预先训练的蛋白质语言模型与深度学习技术相结合,对二级活性转运体进行功能分类并预测相关溶质载体蛋白的能力。这些发现对药物开发、疾病研究以及更广泛地了解细胞转运机制具有重要意义。
{"title":"MCNN-AAPT: accurate classification and functional prediction of amino acid and peptide transporters in secondary active transporters using protein language models and multi-window deep learning.","authors":"Muhammad Shahid Malik, Van The Le, Syed Muazzam Ali Shah, Yu-Yen Ou","doi":"10.1080/07391102.2024.2431664","DOIUrl":"10.1080/07391102.2024.2431664","url":null,"abstract":"<p><p>Secondary active transporters play a crucial role in cellular physiology by facilitating the movement of molecules across cell membranes. Identifying the functional classes of these transporters, particularly amino acid and peptide transporters, is essential for understanding their involvement in various physiological processes and disease pathways, including cancer. This study aims to develop a robust computational framework that integrates pre-trained protein language models and deep learning techniques to classify amino acid and peptide transporters within the secondary active transporter (SAT) family and predict their functional association with solute carrier (SLC) proteins. The study leverages a comprehensive dataset of 448 secondary active transporters, including 36 solute carrier proteins, obtained from UniProt and the Transporter Classification Database (TCDB). Three state-of-the-art protein language models, ProtTrans, ESM-1b, and ESM-2, are evaluated within a deep learning neural network architecture that employs a multi-window scanning technique to capture local and global sequence patterns. The ProtTrans-based feature set demonstrates exceptional performance, achieving a classification accuracy of 98.21% with 87.32% sensitivity and 99.76% specificity for distinguishing amino acid and peptide transporters from other SATs. Furthermore, the model maintains strong predictive ability for SLC proteins, with an overall accuracy of 88.89% and a Matthews Correlation Coefficient (MCC) of 0.7750. This study showcases the power of integrating pre-trained protein language models and deep learning techniques for the functional classification of secondary active transporters and the prediction of associated solute carrier proteins. The findings have significant implications for drug development, disease research, and the broader understanding of cellular transport mechanisms.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"657-666"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes. 基于免疫表观相关基因的宫颈癌分子分类的预后和免疫治疗意义。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-09-23 DOI: 10.1080/07391102.2024.2404545
Aihua Guo, Peilin Zhong, Linghua Wang, Xiurong Lin, Mei Feng

The immunophenoscore (IPS) is an important indicator for evaluating immunotherapy response. This work was designed to establish a prognostic model based on IPS-related genes in cervical cancer. Weighted correlation network analysis (WGCNA) was utilized to identify key modules related to IPS in cervical cancer data from The Cancer Genome Atlas (TCGA). The results show that the yellow module (158 genes) had a high correlation with both IPS_CTLA4_blocker and IPS_CTLA4_and PC1/PDL1/PDL2 blocker. Univariate cox regression analysis and LASSO regression analysis were performed based on 158 genes, and 9 characteristic genes were finally identified to construct the model. According to the differentially expressed genes, cervical cancer samples were divided into high-risk and low-risk groups and cluster 1.2.3. Higher risk scores associated with poorer prognosis. cluster2 and cluster3 were identified as cervical cancer subtypes with significant survival differences. cluster2 had higher immune cell infiltration levels and better prognosis, with greater sensitivity to Cyclopamine, Imatinib, MG-13, Paclitaxel, PHA-665752, Rapamycin, Sorafenib, Sunitinib, and VX-680. In contrast, cluster3 had higher TTN and PIK3CA mutations and greater sensitivity to AZ628, Dasatinib, Doxorubicin, HG-6-64-1, JQ12, Midostaurin, PF-562271, TAE684, and WH-4-023. In conclusion, we developed a feasible risk score model based on IPS-related genes for cervical cancer prognosis and identified potential drugs for different cervical cancer subtypes.

免疫表观评分(IPS)是评估免疫疗法反应的一个重要指标。本研究旨在建立一个基于宫颈癌 IPS 相关基因的预后模型。利用加权相关网络分析(WGCNA)从癌症基因组图谱(TCGA)的宫颈癌数据中识别出与IPS相关的关键模块。结果显示,黄色模块(158个基因)与IPS_CTLA4_blocker和IPS_CTLA4_and PC1/PDL1/PDL2 blocker都有很高的相关性。根据158个基因进行单变量cox回归分析和LASSO回归分析,最终确定了9个特征基因,构建了模型。根据差异表达的基因,宫颈癌样本被分为高风险组和低风险组,并进行1.2.3分组。组群2和组群3的免疫细胞浸润水平较高,预后较好,对环帕胺、伊马替尼、MG-13、紫杉醇、PHA-665752、雷帕霉素、索拉非尼、舒尼替尼和VX-680更敏感。相比之下,群组3的TTN和PIK3CA突变率更高,对AZ628、达沙替尼、多柔比星、HG-6-64-1、JQ12、米多司他林、PF-562271、TAE684和WH-4-023的敏感性更高。总之,我们根据IPS相关基因建立了一个可行的宫颈癌预后风险评分模型,并确定了不同亚型宫颈癌的潜在药物。
{"title":"Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes.","authors":"Aihua Guo, Peilin Zhong, Linghua Wang, Xiurong Lin, Mei Feng","doi":"10.1080/07391102.2024.2404545","DOIUrl":"10.1080/07391102.2024.2404545","url":null,"abstract":"<p><p>The immunophenoscore (IPS) is an important indicator for evaluating immunotherapy response. This work was designed to establish a prognostic model based on IPS-related genes in cervical cancer. Weighted correlation network analysis (WGCNA) was utilized to identify key modules related to IPS in cervical cancer data from The Cancer Genome Atlas (TCGA). The results show that the yellow module (158 genes) had a high correlation with both IPS_CTLA4_blocker and IPS_CTLA4_and PC1/PDL1/PDL2 blocker. Univariate cox regression analysis and LASSO regression analysis were performed based on 158 genes, and 9 characteristic genes were finally identified to construct the model. According to the differentially expressed genes, cervical cancer samples were divided into high-risk and low-risk groups and cluster 1.2.3. Higher risk scores associated with poorer prognosis. cluster2 and cluster3 were identified as cervical cancer subtypes with significant survival differences. cluster2 had higher immune cell infiltration levels and better prognosis, with greater sensitivity to Cyclopamine, Imatinib, MG-13, Paclitaxel, PHA-665752, Rapamycin, Sorafenib, Sunitinib, and VX-680. In contrast, cluster3 had higher TTN and PIK3CA mutations and greater sensitivity to AZ628, Dasatinib, Doxorubicin, HG-6-64-1, JQ12, Midostaurin, PF-562271, TAE684, and WH-4-023. In conclusion, we developed a feasible risk score model based on IPS-related genes for cervical cancer prognosis and identified potential drugs for different cervical cancer subtypes.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"967-982"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, synthesis and biological evaluation of pyrazolo[3,4-b]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity. pyrazolo[3,4-b]吡啶衍生物作为CDK2/PIM1双抑制剂的设计、合成和生物学评价。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2025-03-13 DOI: 10.1080/07391102.2025.2475233
Mahmoud S Elkotamy, Mohamed K Elgohary, Mahmoud Abdelrahman Alkabbani, Faizah A Binjubair, Manal M Alanazi, Marwa Alsulaimany, Sara T Al-Rashood, Hazem A Ghabbour, Hatem A Abdel-Aziz

The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-b]pyridine derivatives (6a-c), confirmed via spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay. Among the tested compounds, 6b exhibited superior efficacy, with higher selectivity indices for HCT-116 (15.05) and HepG2 (9.88) compared to the reference drug staurosporine. Mechanistic studies revealed that 6b induced apoptosis (63.04-fold increase) and arrested the cell cycle at the G0-G1 phase, highlighting its anti-proliferative effects. In an in-vivo solid Ehrlich carcinoma (SEC) mouse model, compound 6b significantly reduced tumor weight and volume, exceeding the efficacy of doxorubicin. Additionally, 6b potently inhibited CDK2 and PIM1 kinases (IC50: 0.27 and 0.67 µM, respectively) and reduced tumor-promoting TNF-alpha expression, as confirmed by histopathological and immunohistochemical studies. Computational analyses, including molecular docking, molecular dynamics simulations, and DFT calculations, provided insights into the binding stability and interaction mechanisms of 6b with CDK2 and PIM1, while in-silico pharmacokinetic and toxicity evaluations confirmed its favorable drug-like profile and safety. This study highlights compound 6b as a promising dual CDK2/PIM1 inhibitor with potent anti-cancer activity and selectivity, paving the way for its further optimization and development as a lead molecule in cancer therapy.

靶向CDK2和PIM1激酶的新型选择性抑制剂的发现对推进癌症治疗至关重要,这些激酶调节细胞存活、增殖和治疗耐药性。本研究报道了三种新型吡唑[3,4-b]吡啶衍生物(6a-c)的设计、合成和生物学评价,并通过光谱分析证实。使用MTT法评估这些化合物对乳腺癌、结肠癌、肝癌和宫颈癌的抗癌活性。其中,6b对HCT-116(15.05)和HepG2(9.88)的选择性指数均高于参比药staurosporine。机制研究表明,6b诱导细胞凋亡(增加63.04倍),使细胞周期阻滞在G0-G1期,突出其抗增殖作用。在体内实体埃利希癌(SEC)小鼠模型中,化合物6b显著降低肿瘤重量和体积,超过阿霉素的效果。此外,经组织病理学和免疫组织化学研究证实,6b能有效抑制CDK2和PIM1激酶(IC50分别为0.27和0.67µM),并降低促肿瘤tnf - α的表达。计算分析,包括分子对接,分子动力学模拟和DFT计算,为6b与CDK2和PIM1的结合稳定性和相互作用机制提供了见解,而计算机药代动力学和毒性评估证实了其良好的药物样谱和安全性。本研究强调了化合物6b作为一种有前景的双CDK2/PIM1抑制剂,具有强大的抗癌活性和选择性,为其进一步优化和开发作为癌症治疗的先导分子铺平了道路。
{"title":"Design, synthesis and biological evaluation of pyrazolo[3,4-<i>b</i>]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity.","authors":"Mahmoud S Elkotamy, Mohamed K Elgohary, Mahmoud Abdelrahman Alkabbani, Faizah A Binjubair, Manal M Alanazi, Marwa Alsulaimany, Sara T Al-Rashood, Hazem A Ghabbour, Hatem A Abdel-Aziz","doi":"10.1080/07391102.2025.2475233","DOIUrl":"10.1080/07391102.2025.2475233","url":null,"abstract":"<p><p>The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-<i>b</i>]pyridine derivatives (<b>6a-c</b>), confirmed <i>via</i> spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay. Among the tested compounds, <b>6b</b> exhibited superior efficacy, with higher selectivity indices for HCT-116 (15.05) and HepG2 (9.88) compared to the reference drug staurosporine. Mechanistic studies revealed that <b>6b</b> induced apoptosis (63.04-fold increase) and arrested the cell cycle at the G0-G1 phase, highlighting its anti-proliferative effects. In an <i>in-vivo</i> solid Ehrlich carcinoma (SEC) mouse model, compound <b>6b</b> significantly reduced tumor weight and volume, exceeding the efficacy of doxorubicin. Additionally, <b>6b</b> potently inhibited CDK2 and PIM1 kinases (IC<sub>50</sub>: 0.27 and 0.67 µM, respectively) and reduced tumor-promoting TNF-alpha expression, as confirmed by histopathological and immunohistochemical studies. Computational analyses, including molecular docking, molecular dynamics simulations, and DFT calculations, provided insights into the binding stability and interaction mechanisms of <b>6b</b> with CDK2 and PIM1, while <i>in-silico</i> pharmacokinetic and toxicity evaluations confirmed its favorable drug-like profile and safety. This study highlights compound <b>6b</b> as a promising dual CDK2/PIM1 inhibitor with potent anti-cancer activity and selectivity, paving the way for its further optimization and development as a lead molecule in cancer therapy.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"1064-1088"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computational simulation guided prediction of the inhibitory effect of curcumin, diallyl sulfide and its conjugates on ALDH1A1 to target breast cancer stem cells (BCSCs). 计算模拟指导预测姜黄素、二烯丙基硫醚及其偶联物对ALDH1A1靶向乳腺癌干细胞(BCSCs)的抑制作用。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2025-05-26 DOI: 10.1080/07391102.2025.2506720
Kanchan Gairola, Gagandeep Singh, Ananya Bahuguna, Rohit Pujari, Rajesh Kumar Kesharwani, Shiv Kumar Dubey

. Despite the significant advancements in clinical and laboratory research, breast cancer remains a formidable challenge due to its high incidence, recurrence and mortality rate. The emerging paradigm emphasizes the pivotal role of cancer stem cells in compelling cancer initiation and recurrence attributed to the resistance against conventional radio and chemotherapy, thereby leading to poor prognosis and disease relapse post-treatment. Aldehyde dehydrogenase (ALDH1A1) is the putative stemness biomarker in breast cancer stem cells. It has been attributed to drug resistance in chemotherapy, especially against the drugs derived from aldehydic intermediate in action mechanism, cell differentiation and oxidative stress response. Since time immemorial, natural products have been employed in traditional medicine systems for their therapeutic and chemopreventive properties. Curcumin, an active polyphenol present in turmeric, plays a significant role in impeding the growth of BCSCs. However, the clinical efficacy of curcumin is restrained due to its poor bioavailability, limited absorption, rapid metabolism, and systemic elimination. To address this challenge, efforts have been directed towards synthesizing curcumin conjugates with diallyl sulfide to enhance its bioavailability. Computational tools such as molecular docking, molecular dynamics simulations and end-state MMGBSA binding free-energy calculations were employed to predict the optimal binding of curcumin conjugates with ALDH1A1 and provide valuable insights into their potential binding affinity and therapeutic efficacy. The enhanced bioavailability of curcumin may be attributed to the enhanced therapeutic activity against the BCSCs. Furthermore, synthesizing curcumin conjugates holds promise in cancer Chemoprevention. .

. 尽管在临床和实验室研究方面取得了重大进展,但由于乳腺癌的高发病率、复发率和死亡率,它仍然是一个巨大的挑战。新出现的范式强调癌症干细胞在抑制癌症起始和复发中的关键作用,这归因于对传统放化疗的抵抗,从而导致预后不良和治疗后疾病复发。醛脱氢酶(ALDH1A1)是乳腺癌干细胞中公认的干细胞性生物标志物。化疗中的耐药,特别是对醛类中间体衍生药物的耐药,在作用机制、细胞分化和氧化应激反应等方面均有研究。自古以来,天然产物因其治疗和化学预防特性而被用于传统医学系统。姜黄素是姜黄中存在的一种活性多酚,在阻碍bscs生长中起着重要作用。但姜黄素的生物利用度差,吸收有限,代谢快,易被全身清除,临床疗效受到限制。为了应对这一挑战,人们一直致力于合成姜黄素与二烯丙基硫醚的缀合物,以提高其生物利用度。利用分子对接、分子动力学模拟和终态MMGBSA结合自由能计算等计算工具预测姜黄素偶联物与ALDH1A1的最佳结合,并为其潜在的结合亲和力和治疗效果提供有价值的见解。姜黄素增强的生物利用度可能是由于姜黄素增强了对BCSCs的治疗活性。此外,合成姜黄素缀合物在癌症化学预防方面具有前景。
{"title":"Computational simulation guided prediction of the inhibitory effect of curcumin, diallyl sulfide and its conjugates on ALDH1A1 to target breast cancer stem cells (BCSCs).","authors":"Kanchan Gairola, Gagandeep Singh, Ananya Bahuguna, Rohit Pujari, Rajesh Kumar Kesharwani, Shiv Kumar Dubey","doi":"10.1080/07391102.2025.2506720","DOIUrl":"10.1080/07391102.2025.2506720","url":null,"abstract":"<p><p>. Despite the significant advancements in clinical and laboratory research, breast cancer remains a formidable challenge due to its high incidence, recurrence and mortality rate. The emerging paradigm emphasizes the pivotal role of cancer stem cells in compelling cancer initiation and recurrence attributed to the resistance against conventional radio and chemotherapy, thereby leading to poor prognosis and disease relapse post-treatment. Aldehyde dehydrogenase (ALDH1A1) is the putative stemness biomarker in breast cancer stem cells. It has been attributed to drug resistance in chemotherapy, especially against the drugs derived from aldehydic intermediate in action mechanism, cell differentiation and oxidative stress response. Since time immemorial, natural products have been employed in traditional medicine systems for their therapeutic and chemopreventive properties. Curcumin, an active polyphenol present in turmeric, plays a significant role in impeding the growth of BCSCs. However, the clinical efficacy of curcumin is restrained due to its poor bioavailability, limited absorption, rapid metabolism, and systemic elimination. To address this challenge, efforts have been directed towards synthesizing curcumin conjugates with diallyl sulfide to enhance its bioavailability. Computational tools such as molecular docking, molecular dynamics simulations and end-state MMGBSA binding free-energy calculations were employed to predict the optimal binding of curcumin conjugates with ALDH1A1 and provide valuable insights into their potential binding affinity and therapeutic efficacy. The enhanced bioavailability of curcumin may be attributed to the enhanced therapeutic activity against the BCSCs. Furthermore, synthesizing curcumin conjugates holds promise in cancer Chemoprevention. .</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"1024-1037"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioinformatics approach reveals the modulatory role of JUN in atorvastatin-mediated anti-breast cancer effects. 生物信息学方法揭示JUN在阿托伐他汀介导的抗乳腺癌作用中的调节作用。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2025-05-12 DOI: 10.1080/07391102.2025.2499950
Mohamed Y Foda, Sara A Al-Shun, Guendouzi Abdelkrim, Mohamed L Salem, Nevin A Salah, Omali Y El-Khawaga

Atorvastatin, a widely prescribed cholesterol-lowering drug, has recently shown potential anticancer effects. However, its influence on gene expression and its biological functions in cancer, in particular breast cancer, still unclear. We aim to identify the dysregulated genes associated with atorvastatin treatment and the main players in their biological network. A total of 103 differentially expressed genes (DEGs) in the unified signature were identified, and the functional enrichment analysis suggested their relation to multiple cancer-related pathways. JUN was identified as the hub gene in the protein-protein interaction (PPI) network and was shown to be responsive to atorvastatin in breast cancer. Atorvastatin exhibited notable predicted cytotoxicity against breast cancer lines, with the activity positively correlated with JUN expression. JUN was significantly downregulated in breast cancer expression inversely correlated with cancer progression, whereas higher JUN expression was linked with better survival outcomes. Atorvastatin may directly interact with JUN protein forming a more compact and stable conformation. These findings demystify the potential therapeutic mechanism of atorvastatin in breast cancer, possibly by fine tuning of JUN expression. As such, JUN might serve as a valuable prognostic biomarker in breast cancer.

阿托伐他汀是一种广泛使用的降胆固醇药物,最近显示出潜在的抗癌作用。然而,其对癌症,特别是乳腺癌中基因表达及其生物学功能的影响尚不清楚。我们的目标是确定与阿托伐他汀治疗相关的失调基因及其生物网络中的主要参与者。在统一签名中共鉴定出103个差异表达基因(deg),功能富集分析表明它们与多种癌症相关途径有关。JUN被确定为蛋白-蛋白相互作用(PPI)网络中的枢纽基因,并被证明对乳腺癌中的阿托伐他汀有反应。阿托伐他汀对乳腺癌表现出显著的预测细胞毒性,其活性与JUN表达呈正相关。JUN在乳腺癌中的表达显著下调与癌症进展呈负相关,而JUN的高表达与更好的生存结果相关。阿托伐他汀可能直接与JUN蛋白相互作用,形成更紧密和稳定的构象。这些发现揭开了阿托伐他汀治疗乳腺癌的潜在机制,可能是通过微调JUN的表达。因此,JUN可能作为一种有价值的乳腺癌预后生物标志物。
{"title":"Bioinformatics approach reveals the modulatory role of JUN in atorvastatin-mediated anti-breast cancer effects.","authors":"Mohamed Y Foda, Sara A Al-Shun, Guendouzi Abdelkrim, Mohamed L Salem, Nevin A Salah, Omali Y El-Khawaga","doi":"10.1080/07391102.2025.2499950","DOIUrl":"10.1080/07391102.2025.2499950","url":null,"abstract":"<p><p>Atorvastatin, a widely prescribed cholesterol-lowering drug, has recently shown potential anticancer effects. However, its influence on gene expression and its biological functions in cancer, in particular breast cancer, still unclear. We aim to identify the dysregulated genes associated with atorvastatin treatment and the main players in their biological network. A total of 103 differentially expressed genes (DEGs) in the unified signature were identified, and the functional enrichment analysis suggested their relation to multiple cancer-related pathways. JUN was identified as the hub gene in the protein-protein interaction (PPI) network and was shown to be responsive to atorvastatin in breast cancer. Atorvastatin exhibited notable predicted cytotoxicity against breast cancer lines, with the activity positively correlated with JUN expression. JUN was significantly downregulated in breast cancer expression inversely correlated with cancer progression, whereas higher JUN expression was linked with better survival outcomes. Atorvastatin may directly interact with JUN protein forming a more compact and stable conformation. These findings demystify the potential therapeutic mechanism of atorvastatin in breast cancer, possibly by fine tuning of JUN expression. As such, JUN might serve as a valuable prognostic biomarker in breast cancer.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"1003-1023"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel breast cancer detection system from mammographic images using a hyperparameter tuned gated recurrent unit with attention included capsnet. 一种利用超参数调谐门控复发单元的新型乳房x线影像乳腺癌检测系统,包括capsnet。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-12-30 DOI: 10.1080/07391102.2024.2442760
M Guru Maheswari, K Karthigadevi, G Elizabeth Rani

Breast cancer (BC) is one of the most fatal diseases that have a profound impact on women. If the cancer is identified earlier, the proper treatment will be provided to the patients to decrease the possibility of death. Mammography is a widely used imaging modality to detect BC earlier, providing valuable information to radiologists to offer better treatment plans and outcomes. This article proposes an efficient BC detection system from mammographic images using a hyperparameter-tuned gated recurrent unit (HTGRU) with attention included in a pre-trained model. The system includes the following steps: preprocessing, segmentation, feature extraction, and classification. The proposed system performs preprocessing using Gaussian filtering and contrast-limited adaptive histogram equalization (CLAHE) for noise removal and contrast enhancement. The data augmentation is performed on the preprocessed dataset to balance the data samples of the benign and malignant classes that prevents the network form biased results. After that, a deviation theory-based fuzzy c-means (DTFCM) algorithm is utilized to segment the tumor regions from the preprocessed image. Then, the most discriminant features are extracted from the segmented tumor regions using a normalization-based attention module incorporated in the capsule network (NAMCN). Finally, HTGRU is used for classification, classifying the data into benign, malignant, and normal. The system is evaluated by the Mammographic Image Analysis Society (MIAS) and curated breast imaging subset of a digital database for screening mammography (CBIS-DDSM) datasets, and the outcomes demonstrate the proposed method's superiority over existing methods by achieving higher detection accuracy and lower false positive rates.

乳腺癌(BC)是对妇女产生深远影响的最致命疾病之一。如果及早发现癌症,就会给予适当的治疗,以减少死亡的可能性。乳房x光检查是一种广泛使用的早期检测BC的成像方式,为放射科医生提供有价值的信息,以提供更好的治疗计划和结果。本文提出了一种有效的乳房x线摄影图像BC检测系统,使用超参数调谐门控循环单元(HTGRU),并将注意力包含在预训练模型中。该系统包括以下几个步骤:预处理、分割、特征提取和分类。该系统使用高斯滤波和对比度限制自适应直方图均衡化(CLAHE)进行预处理,以去除噪声和增强对比度。在预处理后的数据集上进行数据增强,平衡良性和恶性类的数据样本,防止网络形成有偏差的结果。然后,利用基于偏差理论的模糊c均值(DTFCM)算法从预处理图像中分割出肿瘤区域。然后,使用结合在胶囊网络(NAMCN)中的基于归一化的注意力模块,从分割的肿瘤区域中提取最具区别性的特征。最后使用HTGRU进行分类,将数据分为良性、恶性和正常。该系统由乳腺摄影图像分析协会(MIAS)和乳腺摄影筛查数字数据库(CBIS-DDSM)数据集的乳腺成像子集进行评估,结果表明该方法比现有方法具有更高的检测精度和更低的假阳性率。
{"title":"A novel breast cancer detection system from mammographic images using a hyperparameter tuned gated recurrent unit with attention included capsnet.","authors":"M Guru Maheswari, K Karthigadevi, G Elizabeth Rani","doi":"10.1080/07391102.2024.2442760","DOIUrl":"https://doi.org/10.1080/07391102.2024.2442760","url":null,"abstract":"<p><p>Breast cancer (BC) is one of the most fatal diseases that have a profound impact on women. If the cancer is identified earlier, the proper treatment will be provided to the patients to decrease the possibility of death. Mammography is a widely used imaging modality to detect BC earlier, providing valuable information to radiologists to offer better treatment plans and outcomes. This article proposes an efficient BC detection system from mammographic images using a hyperparameter-tuned gated recurrent unit (HTGRU) with attention included in a pre-trained model. The system includes the following steps: preprocessing, segmentation, feature extraction, and classification. The proposed system performs preprocessing using Gaussian filtering and contrast-limited adaptive histogram equalization (CLAHE) for noise removal and contrast enhancement. The data augmentation is performed on the preprocessed dataset to balance the data samples of the benign and malignant classes that prevents the network form biased results. After that, a deviation theory-based fuzzy c-means (DTFCM) algorithm is utilized to segment the tumor regions from the preprocessed image. Then, the most discriminant features are extracted from the segmented tumor regions using a normalization-based attention module incorporated in the capsule network (NAMCN). Finally, HTGRU is used for classification, classifying the data into benign, malignant, and normal. The system is evaluated by the Mammographic Image Analysis Society (MIAS) and curated breast imaging subset of a digital database for screening mammography (CBIS-DDSM) datasets, and the outcomes demonstrate the proposed method's superiority over existing methods by achieving higher detection accuracy and lower false positive rates.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":"44 2","pages":"727-740"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New targets and biomarkers for doxorubicin-induced cardiotoxicity in humans: implications drawn from toxicogenomic data and molecular modelling. 多柔比星诱发人类心脏毒性的新靶点和生物标志物:从毒物基因组学数据和分子建模中得出的启示。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-11-14 DOI: 10.1080/07391102.2024.2427380
Fuat Karakuş, Abdulilah Ece, Burak Kuzu

The doxorubicin-induced cardiotoxicity continues to be a life-threatening adverse effect in the clinic. Doxorubicin-induced acute cardiotoxicity is reversible, whereas chronic cardiotoxicity is irreversible, leading to dilated cardiomyopathy and heart failure. The aim of this study was to identify the molecular mechanisms associated with doxorubicin metabolites in doxorubicin-induced chronic cardiotoxicity. For this purpose, literature searches and in silico toxicogenomic analyses were conducted using various tools, including the Comparative Toxicogenomic Database, GeneMANIA, Metascape, MIENTURNET, ChEA3, and AutoDock. Additionally, molecular dynamics simulations were performed for 500 ns using Schrödinger software to assess the stability and dynamics of the representative docked complexes. We observed that doxorubicin biotransformed into five metabolites in the human heart and identified 11 common genes related to doxorubicin, its metabolites, dilated cardiomyopathy, and heart failure. Our findings revealed that doxorubicin and its metabolites primarily exhibited binding affinity to the beta-1 adrenergic receptor and fatty acid synthase. Furthermore, we identified several key transcription factors, especially the Homeobox protein Nkx-2.6, and hsa-miR-183-3p associated with this cardiotoxicity. Finally, we observed that, in addition to doxorubicinol, 7-deoxidoxorubicinone, another metabolite of doxorubicin, may also contribute to this cardiotoxicity. These findings contribute to our understanding of the processes underlying doxorubicin-induced chronic cardiotoxicity.

在临床上,多柔比星诱发的心脏毒性仍然是一种危及生命的不良反应。多柔比星诱发的急性心脏毒性是可逆的,而慢性心脏毒性是不可逆的,会导致扩张型心肌病和心力衰竭。本研究旨在确定多柔比星代谢物在多柔比星诱导的慢性心脏毒性中的相关分子机制。为此,我们使用多种工具进行了文献检索和硅学毒物基因组分析,包括比较毒物基因组数据库、GeneMANIA、Metascape、MIENTURNET、ChEA3 和 AutoDock。此外,还使用薛定谔软件进行了 500 ns 的分子动力学模拟,以评估代表性对接复合物的稳定性和动力学。我们观察到多柔比星在人类心脏中生物转化为五种代谢物,并确定了与多柔比星、其代谢物、扩张型心肌病和心力衰竭相关的 11 个常见基因。我们的研究结果表明,多柔比星及其代谢物主要表现出与β-1肾上腺素能受体和脂肪酸合成酶的结合亲和力。此外,我们还发现了几个与这种心脏毒性相关的关键转录因子,特别是 Homeobox 蛋白 Nkx-2.6 和 hsa-miR-183-3p。最后,我们观察到,除了多柔比星醇之外,多柔比星的另一种代谢产物 7-脱氧多柔比星酮也可能导致这种心脏毒性。这些发现有助于我们了解多柔比星诱发慢性心脏毒性的基本过程。
{"title":"New targets and biomarkers for doxorubicin-induced cardiotoxicity in humans: implications drawn from toxicogenomic data and molecular modelling.","authors":"Fuat Karakuş, Abdulilah Ece, Burak Kuzu","doi":"10.1080/07391102.2024.2427380","DOIUrl":"10.1080/07391102.2024.2427380","url":null,"abstract":"<p><p>The doxorubicin-induced cardiotoxicity continues to be a life-threatening adverse effect in the clinic. Doxorubicin-induced acute cardiotoxicity is reversible, whereas chronic cardiotoxicity is irreversible, leading to dilated cardiomyopathy and heart failure. The aim of this study was to identify the molecular mechanisms associated with doxorubicin metabolites in doxorubicin-induced chronic cardiotoxicity. For this purpose, literature searches and <i>in silico</i> toxicogenomic analyses were conducted using various tools, including the Comparative Toxicogenomic Database, GeneMANIA, Metascape, MIENTURNET, ChEA3, and AutoDock. Additionally, molecular dynamics simulations were performed for 500 ns using Schrödinger software to assess the stability and dynamics of the representative docked complexes. We observed that doxorubicin biotransformed into five metabolites in the human heart and identified 11 common genes related to doxorubicin, its metabolites, dilated cardiomyopathy, and heart failure. Our findings revealed that doxorubicin and its metabolites primarily exhibited binding affinity to the beta-1 adrenergic receptor and fatty acid synthase. Furthermore, we identified several key transcription factors, especially the Homeobox protein Nkx-2.6, and hsa-miR-183-3p associated with this cardiotoxicity. Finally, we observed that, in addition to doxorubicinol, 7-deoxidoxorubicinone, another metabolite of doxorubicin, may also contribute to this cardiotoxicity. These findings contribute to our understanding of the processes underlying doxorubicin-induced chronic cardiotoxicity.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"1038-1050"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer. 非小细胞肺癌早期诊断、预后和治疗的综合生物信息学方法。
IF 2.4 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-02-01 Epub Date: 2024-11-13 DOI: 10.1080/07391102.2024.2425840
Adiba Sultana, Md Shahin Alam, Alima Khanam, Yuxin Lin, Shumin Ren, Rajeev K Singla, Rohit Sharma, Kamil Kuca, Bairong Shen

Non-small-cell lung cancer (NSCLC) is one of the most deadly tumors characterized by poor survival rates. Advances in therapeutics and precise identification of biomarkers can potentially reduce the mortality rate. Thus, this study aimed to identify a set of common and stable gene biomarkers through integrated bioinformatics approaches that might be effective for NSCLC early diagnosis, prognosis, and therapies. Four gene expression profiles (GSE19804, GSE19188, GSE10072, and GSE32863) downloaded from the Gene Expression Omnibus database to identify common differential expressed genes (DEGs). A total of 213 overlapping DEGs (oDEGs) between NSCLC and healthy samples were identified by using statistical LIMMA method. Then 6 common top-ranked key genes (KGs) (CENPF, CAV1, ASPM, CCNB2, PRC1, and KIAA0101) were selected by using four network-measurer methods in the protein- protein interaction network. The GO functional and KEGG pathway enrichment analysis were performed to reveal some significant functions and pathways associated with NSCLC progression. Transcriptional and post-transcriptional factors of KGs were identified through the regulatory interaction network. The prognostic power and expression level of KGs were validated by using the independent data through the Kaplan-Meier and Box plots, respectively. Finally, 4 KGs-guided repositioning candidate drugs (ZSTK474, GSK2126458, Masitinib, and Trametinib) were proposed. The stability of three top-ranked drug-target interactions (CAV1 vs. ZSTK474, CAV1 vs. GSK2126458, and ASPM vs. Trametinib) were investigated by computing their binding free energies for 140 ns MD-simulation based on MM-PBSA approach. Therefore, the findings of this computational study may be useful for early prognosis, diagnosis and therapies of NSCLC.

非小细胞肺癌(NSCLC)是最致命的肿瘤之一,其特点是生存率低。治疗方法的进步和生物标志物的精确鉴定有可能降低死亡率。因此,本研究旨在通过综合生物信息学方法鉴定一组常见且稳定的基因生物标记物,这些标记物可能对 NSCLC 早期诊断、预后和治疗有效。研究人员从基因表达总库(Gene Expression Omnibus)数据库下载了四份基因表达图谱(GSE19804、GSE19188、GSE10072和GSE32863),以确定常见的差异表达基因(DEGs)。通过 LIMMA 统计方法,共鉴定出 213 个 NSCLC 和健康样本之间的重叠 DEGs(oDEGs)。然后,利用蛋白质-蛋白质相互作用网络中的四种网络测量方法筛选出 6 个常见的排名靠前的关键基因(KGs)(CENPF、CAV1、ASPM、CCNB2、PRC1 和 KIAA0101)。通过GO功能分析和KEGG通路富集分析,发现了一些与NSCLC进展相关的重要功能和通路。通过调控相互作用网络确定了KGs的转录和转录后因子。利用独立数据,通过Kaplan-Meier图和方框图分别验证了KGs的预后能力和表达水平。最后,提出了4种KGs指导的重新定位候选药物(ZSTK474、GSK2126458、马西替尼和曲美替尼)。通过基于MM-PBSA方法的140 ns MD模拟计算,研究了三种排名靠前的药物-靶点相互作用(CAV1 vs. ZSTK474、CAV1 vs. GSK2126458和ASPM vs. Trametinib)的结合自由能的稳定性。因此,这项计算研究的结果可能有助于NSCLC的早期预后、诊断和治疗。
{"title":"An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer.","authors":"Adiba Sultana, Md Shahin Alam, Alima Khanam, Yuxin Lin, Shumin Ren, Rajeev K Singla, Rohit Sharma, Kamil Kuca, Bairong Shen","doi":"10.1080/07391102.2024.2425840","DOIUrl":"10.1080/07391102.2024.2425840","url":null,"abstract":"<p><p>Non-small-cell lung cancer (NSCLC) is one of the most deadly tumors characterized by poor survival rates. Advances in therapeutics and precise identification of biomarkers can potentially reduce the mortality rate. Thus, this study aimed to identify a set of common and stable gene biomarkers through integrated bioinformatics approaches that might be effective for NSCLC early diagnosis, prognosis, and therapies. Four gene expression profiles (GSE19804, GSE19188, GSE10072, and GSE32863) downloaded from the Gene Expression Omnibus database to identify common differential expressed genes (DEGs). A total of 213 overlapping DEGs (oDEGs) between NSCLC and healthy samples were identified by using statistical LIMMA method. Then 6 common top-ranked key genes (KGs) (CENPF, CAV1, ASPM, CCNB2, PRC1, and KIAA0101) were selected by using four network-measurer methods in the protein- protein interaction network. The GO functional and KEGG pathway enrichment analysis were performed to reveal some significant functions and pathways associated with NSCLC progression. Transcriptional and post-transcriptional factors of KGs were identified through the regulatory interaction network. The prognostic power and expression level of KGs were validated by using the independent data through the Kaplan-Meier and Box plots, respectively. Finally, 4 KGs-guided repositioning candidate drugs (ZSTK474, GSK2126458, Masitinib, and Trametinib) were proposed. The stability of three top-ranked drug-target interactions (CAV1 vs. ZSTK474, CAV1 vs. GSK2126458, and ASPM vs. Trametinib) were investigated by computing their binding free energies for 140 ns MD-simulation based on MM-PBSA approach. Therefore, the findings of this computational study may be useful for early prognosis, diagnosis and therapies of NSCLC.</p>","PeriodicalId":15272,"journal":{"name":"Journal of Biomolecular Structure & Dynamics","volume":" ","pages":"914-928"},"PeriodicalIF":2.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Biomolecular Structure & Dynamics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1